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Abstract
There has been a significant increase in our understanding of the host genetic determinants of susceptibility to viral infections in recent years.
Recently, two single-nucleotide polymorphisms (SNPs), rs12979860 T/C and rs8099917 T/G, upstream of the interleukin (IL)-28B/interferon
(IFN)-k3 gene have been clearly associated with spontaneous and treatment-induced viral clearance in hepatitis C virus (HCV) infection.
Because of their power in predicting the response to IFN/ribavirin therapy, the above SNPs have been used as a diagnostic tool, even though
their relevance in themanagement of HCV infection will be blunt in the era of IFN-free regimens. The recent discovery of a new genetic variant,
ss469415590 TT/DG, upstream of the IL-28B gene, which generates the novel IFN-k4 protein, has opened up a new and alternative scenario to
understand the functional architecture of type III IFN genomic regions and to improve our knowledge of the pathogenetic mechanism of HCV
infection. A role of ss469415590 in predicting responsiveness to antiviral therapy has also been observed in HCV-infected patients receiving
direct antiviral agents. The underlying biological mechanism that links the above IL-28B polymorphisms (in both IFN-k3 and IFN-k4) to
spontaneous and treatment-induced clearance ofHCV infection remains to be discovered. Despite this, shedding some light on this issue, which
is the main aim of this review, may provide new insights into the general topic of ‘host genetics and viral infections’.
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Introduction
In recent years, there has been a significant improvement in
our understanding of the host genetic and genomic determi-
nants of susceptibility to viral infections, disease progression,
and response to antiviral therapy. Indeed, common variants in
some host loci that clearly influence viral disease progression
have been documented at all levels, i.e. viral receptors,
Toll-like receptors, DNA sensors, restriction factors, induc-
tion and production of cytokines, and/or the immune function
of specific cellular effectors. A long list of host genes
potentially affecting the natural course of viral diseases and
the effectiveness of antiviral therapy can therefore be
provided. Table 1 shows the main consolidated host genetic
variants involved in treatment response in patients suffering
from chronic viral infections.
Nevertheless, it should be mentioned that, due to the
rapid moving of the issue, it is quite difficult to obtain a full
picture of the field at present. This is why this review will
focus only on the specific and limited issue of the
association of common single-nucleotide polymorphisms
(SNPs) in the interferon (IFN)-k gene with disease outcome
and treatment response in chronic hepatitis C (CHC). We
believe that this is one of the best characterized examples
of the interplay between host genetics and chronic viral
infection that strongly suggests the consideration of individ-
ualization of antiviral therapy to effectively control viral
infections.
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IFN and Hepatitis C Virus (HCV) Infection
Infection by HCV, which was discovered only in 1989 with
molecular techniques [1], represents a significant global health
issue, with an estimated prevalence of 130–200 million
infected individuals worldwide. So far, on the basis of their
genome sequences, six major genotypes (designated 1–6) and
several subtypes (named in alphabetical order from ‘a’) of HCV
have been characterized. It is well known that the genotypes of
HCV differ mainly in their response to antiviral therapy.
Acute HCV infections are usually asymptomatic and, even in
western countries, very rarely diagnosed. In some of the
infected subjects, the infection is spontaneously eradicated, but
the virus may persist in a high percentage (70–80%) of the
infected individuals, leading to CHC. These subjects are at risk
(15–25%) of developing liver cirrhosis and hepatocarcinoma
after 10–40 years of infection, owing to the continuing
necrosis and inflammation in the liver.
Until recently, the standard antiviral therapy was based on
IFN-a, a virus-induced cytokine that is rapidly produced in the
liver of HCV-infected subjects during the first 4–10 weeks of
infection, and that is able to induce the expression of a number
of specific genes, collectively called IFN-stimulated genes (ISGs),
coding for proteins with direct or indirect antiviral properties.
This therapy has undergone significant evolution and improve-
ment over the years [from 1989 to 2012, when pegylated IFN
(PEG) and the nucleoside analog ribavirin (RBV) were used],
allowing a complete virological response (i.e. the disappear-
ance of the virus from the blood) to be obtained in
approximately 50% of the patients infected with HCV geno-
type 1 (GT1 HCV), the most widely distributed and
IFN-a-resistant genotype of HCV. Actually, several new drugs
(with both host and virus targets), which are expected to cure
>90% of HCV infections, have reached or are going to reach
the market, probably making IFN-free regimens available in the
near future.
Since the beginning of IFN therapy, it was evident that a
proportion of patients did not respond to the therapy or
relapsed after an initial response, and a significant variability in
response, even early after the first injection of IFN [2], could
be demonstrated. This issue was addressed very intensely, and
soon many viral and host factors affecting the treatment
response were identified (e.g. viral genotype, viral load level,
and wideness of viral quasi-species variability at the beginning
of therapy; acute vs. chronic infection; gender and age; level of
fibrosis; body mass index and weight; insulin resistance; and
presence of comorbidities). In the meantime, it was being
recognized that the above factors could only partially explain
the IFN response variability, and that, on the basis of the
relevance of ethnicity to the outcome of the disease, the
response to IFN may also have a genetic basis. Thus,
researchers started to believe that there could be other
important factors, mainly host genetic factors, that played a
pivotal role in the natural course of the disease, and that could
also profoundly affect the response to antiviral therapy based
on a biological modifier, such as IFN.
TABLE 1. Main host genomic determinants and therapy outcome
Acronym Infection Effect References
Interleukin-28B IL-28B HCV Spontaneous clearance and treatment response (SVR) 15–18
rs12979860 (T/C) and rs8099917 (T/G)
Interferon-k4 IFN-k4 HCV Spontaneous clearance and treatment response (SVR) 13,64–66
ss469415590 or rs368234815 IFN-k4-TT/DG
Inosine triphosphate tyrophosphatase ITPA HCV Ribavirin reduced anaemia induced by ITP deficiency 70
rs6051702 (A/C) rs1127354 (C/C, A/C, A/A),
s7270101 (A/A, A/C, C/C)
Vitamin D receptor VDR HCV Treatment response (SVR) 71
rs2228570 (T/C)
Human leukocyte antigen C HLA-C HCV Treatment response 72
HLA-C (C1/C2)
Killer immunoglobulin-like receptors KIR HCV Treatment response (SVR) 72
KIR2DL2 or 2DL3
KIR2DL3 in combination with HLAC2C2
Human leukocyte antigen A HLA HCV Treatment response (SVR) 73
HLA-DQB1*0301 and HLA-A*0201 in
synergism with rs12979860 CC
Low-density lipoprotein cholesterol
receptor
LDLR HCV Treatment response (SVR) 74
LDRL levels
Human cytochrome P450 2B6 CYP2B6 HIV Efavirenz treatment decision and discontinuation 75
CYP2B6 516 (T/T) genotype is associated with
higher efavirenz plasma exposure and increased
CNS toxicity
Human leukocyte antigen B HLAB*5701 HIV Abacavir treatment decision and discontinuation 76
Development of immune-mediated hypersensitivity
reaction to abacavir
Human leukocyte antigen A HLA-DRB*0101 HIV Nevirapine treatment decision and discontinuation 75
Nevirapine-associated hypersensitivity
CNS, central nervous system; HCV, hepatitis C virus; ITP, inosine triphosphate; SVR, sustained virological response.
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A number of studies were tentatively published on the issue
[3–11], until genome-wide association studies (GWASs), which
allowed study of the association between mapped SNPs and
the presence of common conditions in large patient cohorts,
provided evidence that host genetic factors may profoundly
affect the natural history of many diseases, including CHC and
its treatment. Specifically, these studies demonstrated a strong
association between the presence of variants in the IFN-k3
(also known as interleukin (IL)-28B) genetic region and the
PEG/RBV treatment response in CHC.
This article reviews the history and the impact of the
breathtaking discoveries that led to the characterization of this
issue and to the discovery of a completely new and
unexpected way to consider the response to IFN therapy.
IFN-k family
Briefly, IFNs are currently categorized into three different
families: type I IFNs (IFN-a and IFN-b, with least 13
subtypes), type II IFN (IFN-c), and type III IFN (IFN-k1–4)
(Table 2). The last of these types has only recently been
characterized. IFN-ls 1–3 overlap with the previously
identified IL-28 and IL-29, and their genes all mapped
together on chromosome 19 (Fig. 1). Specifically, the IL-28B
gene resides on the short arm of chromosome 19 (19q13.13)
and encodes IFN-k3, which, together with IFN-k1 (IL-29),
IFN-k2 (IL-28A) [12], and IFN-k4 [13], constitutes the IFN-k
family. Owing to their molecular structure, type III IFNs
belong to the IL-10 superfamily, but functionally they are
closely related to type I IFNs, which play a major role in
antiviral immunity [14]. Like type I IFNs, IFN-ks can be
triggered by viral infections and, through interaction with
specific receptors distinct from those of type I IFNs, may
induce antiviral, immunomodulatory and antitumour activity
and the expression of ISGs, although to a different extent to
type I IFNs and with different kinetics.
Genetics of IFN-k3/IL-28B: association with treatment of
chronic hepatitis and the natural course of HCV infection
As already stated, in 2009 and 2010, four independent GWASs
on treatment response to PEG/RBV in CHC patients were
published [15–18]. In each of these GWASs, only SNPs around
the IL-28B gene reached genome-wide significance for treat-
ment outcome and were significantly associated with sponta-
neous and treatment-induced viral clearance in GT1
HCV-infected patients, called the sustained virological
response (SVR).
TABLE 2. Main characteristics of human interferons (IFNs)
IFN-a IFN-b IFN-e IFN-j IFN-x IFN-c IFN-k
Type of IFN I I I I I II III
Chromosomal localization 9 9 9 9 9 12 19
Gene structure Intronless Intronless Intronless Intron Intronless Introns Introns
No. of subtypes 13 1 1 1 1 1 4a
Receptor IFN-AR1/R2 IFN-AR1/R2 IFN-AR1/R2 IFN-AR1/R2 IFN-AR1/R2 IFN-GR1/R2 IL-28R1/IL-10R2
aIFN-k1 (interleukin (IL)-29), IFN-k2 (IL-28A), IFN-k3 (IL-28B), IFN-k4 (dinucleotide genetic variant ss469415590 DG; ref. 13 in the text).
Chromosome 19
q12 q13.2p13.3 p13.2 q13.3p13.1 p12
IFN-λ3 (IL-28B) IFN-λ4 IFN-λ2 (IL-28A) IFN-λ1 (IL-29A)
rs 12979860 SNP ss 469415590 ΔG
ss 469415590 TT 
Frameshift 
rs 8099917 SNP
TT/ΔGC
C
T/GT TT/CG
G
Good response TT
Poor response GG
Good response CC
Poor response TT
FIG. 1. Interferon (IFN)-k3 and IFN-k4
variants on chromosome 19. IL,
interleukin; SNP, single-nucleotide
polymorphism.
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Although many different SNPs were initially tagged in or
near the IL-28B region (i.e. rs12980275, rs8103142, rs8105790,
rs1188222, rs8099917, rs12979860, etc.) only two of them,
namely rs12979860 T/C and rs8099917 T/G, were subse-
quently confirmed to be relevant in treatment outcome
(Fig. 1). Because all tagged SNPs were in strong linkage
disequilibrium, it was concluded that the association initially
observed for the other SNPs was mainly driven by the two
major SNPs, rs12979860 and rs8099917 [16], although, at that
time, it was not possible to conclude which was the causal
variant. Consistently, rs12979860 C (good-response allele) vs.
T (poor-response allele) and rs8099917 T (good-response
allele) vs. G (poor-response allele) showed the strongest
association among those so far characterized.
Both rs12979860 and rs8099917 SNPs are in linkage
disequilibrium, and their relative allele and genotype frequen-
cies vary among races. In particular, the favourable CC
genotype was more common in Caucasians than in African–
Americans, and it was estimated that frequency of this
genotype was responsible for approximately half of the
recognized discrepancy in the treatment response rates
between the two populations. Random sampling of healthy
populations then identified the rs12979860 CC genotype as
the most common in Asian patients, suggesting that this
genetic variant may also contribute to the high response rates
that have been reported in Asians [19]. Also, the allele
frequencies of rs8099917 differ worldwide, making its power
in predicting an SVR weak in African–Americans [15]. In most
studies, the rs12979860 CC genotype was associated with a
more than two-fold higher chance of achieving an SVR than the
TT genotype. These findings were comparable in patients of
European–American, African–American and Hispanic ancestry,
although SVR rates in African–American patients were gener-
ally lower than those in European–American patients. A more
recent study on selected populations confirmed that the
rs12979860 CC genotype is the strongest pretreatment
predictor of response [20–22], and that it is independent of
other pretreatment clinical predictors, including HCV geno-
type. Some of these studies also demonstrated that the
rs12979860 genotype is strongly associated with very early
on-treatment viral kinetics [21], which, in turn, leads to a more
rapid virological response (RVR). Thus, the association of
IL-28B SNPs with RVR and SVR appears to be related to a
strong impact on very early kinetics during treatment, which
may reflect the antiviral effectiveness of IFN-a. Some GWASs
[16–18] and recently published studies [22] have indepen-
dently identified the rs8099917 GG genotype as the strongest
marker of treatment failure, independently of other clinical
variables. All together, these data support that the idea that
the rs12979860 CC genotype is more efficient in predicting
treatment response in GT1 HCV patients than the rs8099917
TT genotype, whereas the unfavourable rs8099917 GG
genotype seems to be more important in predicting failure
of treatment response.
Data supporting a role for IL-28B genetic variation in
spontaneous viral clearance followed rapidly after, or were
obtained concomitantly with, the discovery of its role in the
treatment response. Indeed, between 2009 and 2010,
rs12979860 was shown to be strongly associated with
spontaneous HCV clearance in patients with acute hepatitis C
[23], with the favourable rs12979860 CC genotype being
mainly linked to jaundice and spontaneous HCV resolution
[24]. These data were extended to rs8099917 by a second
group, who suggested that the non-favourable rs8099917 GG
genotype is a common genetic variant negatively associated
with the spontaneous clearance of HCV infection [18].
In addition to their striking role in spontaneous and
treatment-induced clearance, IL-28B genetic variations seem
to be linked to various phenotypes in HCV infection.
Good-response alleles were, indeed, associated with the
activity of CHC in terms of more severe necroinflammation
in liver biopsies, and with high alanine aminotransferase,
aspartate aminotransferase [25], apolipoprotein B100, and
c-glutamyl transpeptidase [26]. Moreover, a significant associ-
ation of the rs12979860 CC genotype with higher low-density
lipoprotein levels and other serum lipid parameters was
observed in HCV-infected patients [27].
Conflicting data have been published on the association
between IL-28 polymorphisms and the risk of HCV-related
cirrhosis and fibrosis; however, it is generally accepted that
IL-28 SNPs may influence the frequency of steatosis [28]. The
effect of genetic IL-28B variations on spontaneous and
treatment-induced clearance of HCV infection, as well as on
the natural course of infection, points to an important role of
IFN-ks in the pathogenesis and management of CHC, but the
underlying mechanism and its effectors are largely unknown.
In this regard, it has been intriguingly suggested that other
host factors, related or not related to IL-28, may have an
additive effect with IL-28B SNPs in predicting spontaneous
virus clearance and/or treatment response in both acute and
chronic HCV infection. Among these are: pretreatment plasma
levels of IFN-c-inducible protein 10 [29,30]; serum levels of
vitamin D [31]; HLA-C antigen (HLAC2C2) or immunoglob-
ulin-like receptors (KIR2DL3 and KIR2DS1) [32]; and expres-
sion levels of specific HLA class II genes (DQB1*0301) [33].
Other studies suggest that SNP rs10903035 at IL-28 recep-
tor-a is associated with the early treatment failure in human
immunodeficiency virus–HCV-coinfected patients, and it has
been proposed that the combination of IL-28B and IL-28
receptor-a polymorphisms might be a valuable tool for
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predicting early treatment failure before starting HCV treat-
ment [34].
Altogether, the above evidence supports the existence of a
very complex interplay between host genetic and biochemical,
inflammatory and immune factors, among which IFN-k finally
leads to the regulation of the HCV infection response.
Genetics of IFN-k3/IL-28B in infection with HCV genotypes
other than genotype 1
Most of the initial studies on IL-28B and HCVwere focused GT1
HCV infections, because this HCV genotype was the most
resistant to IFN-based therapy. Several studies have clearly
shown that the associations between IL-28B SNPs and RVR/SVR
inHCV genotype 4 patients were comparable to those obtained
for GT1 HCV subjects [18,35]. In contrast, data on IL-28B in
patients infected with HCV genotype 2 (GT2 HCV) and HCV
genotype 3 (GT3 HCV) have produced conflicting data and are
few in number. All studies in GT2 HCV/GT3 HCV patients
yielded mixed results, although most of them failed to show a
significant association between IL-28B and an SVR [36–39]. The
scenario is different if one considers GT3 HCV separately or
uses an adequate sample size. In fact, it has been recently
reported from the largest studies that the rs12979860 CC
genotype is an independent predictive factor for an SVR also in
GT3 HCV patients, whereas no association with an SVR in GT2
HCV infection was observed [40,41]. These data clearly suggest
the relevance of sample size in determining the correlation
between IL-28B genotype and RVR/SVR, and suggest a rationale
for testing IL-28B genotyping also in patients with GT3 HCV.
Effects of genetics of IFN-k3/IL-28B on the mechanism of IFN
action
Although the associations between IL-28B SNPs and the
outcome of treated and untreated CHC patients have been
repeatedly confirmed, the mechanism by which these changes
influence the treatment response and the spontaneous clear-
ance of HCV is still unknown, and no resulting phenotype has
been associated with specific SNPs. Below, some consider-
ations are presented that make clear that the phenomenon is
very complex and that further studies are warranted to draw
definite conclusions on the issue.
First, it is important to note that nearly all IL-28B genetic
variations associated with spontaneous and treatment-induced
clearance are not located within coding regions; they are
located only in close proximity to the IL-28B coding region.
With fine-mapping strategies, only a non-synonymous coding
variation (rs8103142) in exon 2 of IL-28B was identified, but
thus far no functional differences between the resulting
variants (Lys70Arg) have beeen recorded [42]. Thus, it has
been proposed that, even without a direct impact on IFN
protein production or structure, these polymorphisms may
exert a functional effect through regulation of gene expression,
mRNA splicing of receptors, and/or binding/activation of other
cytokines.
Because IFN-ks seems to affect viral replication and control
the infection [43], it was reasonable to consider the possibility
that the expression level of endogenous IFN-k3 could be
influenced by genetic variants. Recent data suggest that IL-28B
SNPs may affect IFN-k expression via altering DNA methyl-
ation and transcription factor-binding sites [44]. Nevertheless,
data on the expression levels in patients with different IL-28B
genotypes remain conflicting, and only a few studies have
shown higher IFN-k3 mRNA levels in the liver and/or blood of
patients with good-response alleles [16,17,45].
In contrast, and perhaps more importantly, a number of
studies have clearly demonstrated that the IL-28Bpoor-response
minor alleles (both rs120979860and rs8099917) are significantly
associated with high levels of ISG expression[42,46,47]. The
initially unexpected high expression levels of pretreatment ISGs
in non-responders have been repeatedly reported [3,48–51],
and the confirmed association between IL-28B genetic variations
and ISG expression, other than confirming that, paradoxically,
pre-activation of the IFN system and/or high expression levels of
ISGs may represent one of the strongest predictors of
non-response to IFN therapy, indicates that the presence of
minor alleles of IL-28B may result in a phenotype with a limited
action of IFN-mediated and IFN-inducible defence.
In light of the above considerations, it could be speculated
that the poor-response allele might be associated with high
expression levels of IFN-signalling inhibitors, leading to a
persistent, but ineffective, high level of activation of ISG
expression triggered by the intracellular HCV genome. By
contrast, the good-response allele might be associated with
fully functional IFN-related endogenous effectors that are able
to clear HCV and are still able to respond to IFN when it is
administered exogenously [26,52]. However, considering also
that, in uninfected subjects, no association between ISG
expression and IL-28 genotype has been demonstrated [53],
such an explanation might not provide any insights into the
direct link between IL-28B genetic variants and IFN-k3. Thus,
the underlying biological mechanism that links IL-28B poly-
morphisms to spontaneous and treatment-induced clearance
of HCV infection remains to be discovered.
Genetics of IFN-k3/IL-28B in the era of direct antiviral agents
(DAAs)
As stated, the standard of care for patients with chronic
hepatitis C has consisted, until recently, of a combination of
PEG and RBV administered for 24–48 weeks, depending on
the HCV genotype. The SVR rate for this standard of care has
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been only approximately 50% in patients infected with GT1
HCV, the most prevalent genotype in Europe and North
America. The therapy of CHC was revolutionized by the
approval in 2011 of two direct antiviral agents (DAAs): the
NS3/4A serine protease inhibitors boceprevir and telaprevir.
The use of these DAAs in combination therapy with PEG/
RBV opened a new era in the field of CHC therapy, mainly in
GT1 HCV-infected patients. Triple therapy in previously
untreated patients raised overall SVR rates from 40–45% to
68–79% [54,55]. All studies on boceprevir/telaprevir showed
an attenuated impact of IL-28B variants on the SVR, even
though patients with a favourable rs12979869 CC genotype
are more likely to be eligible for shorter treatment duration.
In treatment-na€ıve patients or those subsequently treated
with a combination of the ‘second wave’ NS3 protease
inhibitor simeprevir and PEG/RBV, IL-28B genotype has shown
a significant impact on the outcome of treatment [56–58].
Furthermore, the NEUTRINO study (NS5B nucleoside inhib-
itor sofosbuvir plus PEG/RBV) [59] identified the rs12979860
SNP as an independent pretreatment predictor of an SVR.
More recently, data from INFORM-1 (the nucleoside poly-
merase inhibitor mericitabin plus the protease inhibitor
danoprevir) [60] and SOUND-C2 (the protease inhibitor
faldaprevir plus the non-nucleoside polymerase inhibitor
delobuvir) [61] seemed to support a significant impact of
IL-28B genotype also in IFN-free regimens, owing to the effects
of such polymorphisms on the kinetics of viral decay.
It is commonly believed that the effect of the genetics of
IL-28B will be less effective as more potent agents and
combinations (with response rates up to almost 100%) become
available. In fact, data from phase III studies with new DAA
combinations, especially those involving sofosbuvir in combina-
tionwithNS5A inhibitors (daclatasvir or ledipasvir), have shown
that it is possible to achieve high SVR rates independently of
IL-28B genotype [62,63]. Thus, the impact of IL-28B polymor-
phism in some all-oral IFN-free regimens seems to be moderate
even more data are needed to evaluate the actual influence of
IL-28B genotype on treatment success in such regiments,
especially for highly active regimens combining two or three
different DAA classes. It is, however, important to note that,
despite the moderate effect in some regimens, pretreatment
determination of IL-28B genotype might still have some use,
especially considering that IFN-free treatment will not afford-
able in many parts of the world in the near future. Indeed, it is to
be expected that, in developing countries and even in most
countries of eastern Europe, IFN and RBV will constitute the
backbone of antiviral treatment for CHC in the coming years.
The determination of IL-28B genotype might maintain its value in
individualizing therapy to optimize cost-effectiveness and avoid
side effects.
Genetics of IFN-k4: association with treatment of chronic
hepatitis and the natural course of HCV infection
Recently, a dinucleotide frameshift variant in ss469415590 TT/
DG (also designated rs368234815 TT/DG; IFN-k4-TT/DG)
upstream of and in the same orientation as IFN-k3was described
on chromosome 19q13.13; this generates a novel IFN-k pro-
tein, designated IFN-k4, which shares only 29% homology at the
amino acid level with the other three IFN-ks [13,64]. IFN-k4 can
be produced by individuals who carry the minor DG allele of the
ss469415590 variant (IFN-k4-DG), whereas the presence of the
major TT allele leads to a frameshift in exon 1 and disrupts the
IFN-k4 open reading frame, favouring HCV clearance and
improving the outcome after IFN–RBV combination treatment.
The rs12979860 and rs8099917 IL-28B SNPs are located 367 bp
downstream (intron 1) and 4 kb upstream of ss469415590,
respectively. It has also been observed that the IFN-k4-creating
ss469415590 DG allele is perfectly correlated with the unfa-
vourable rs12979860 T allele in Asians and is well correlated in
Europeans, whereas inAfricans this correlation is onlymoderate
[13]. The correlation between ss469415590 and rs8099917 was
high in Asians and moderate in Europeans, but very low in
Africans [13]. The ss469415590 SNP seems to be a better
marker than the rs12979860 SNP in predicting PEG/RBV
treatment response in CHC and possibly spontaneous HCV
clearance in African–Americans, whereas these variants seem to
be similarly informative in European–Americans [13]. This
polymorphism also appears to be a better marker than
rs12979860 in identifying human immunodeficiency virus–
HCV-co-infected patients who do not respond to antiviral
therapy [65]. Furthermore, IFN-k4 polymorphism has been
shown to be independently associated with RVR in all viral
genotypes (GT1 HCV to GT4 HCV4) and with an SVR in GT1
HCV/GT4 HCV, but not in GT2 HCV/GT3 HCV [66]. Interest-
ingly a role of ss469415590 (TT orDG) in predicting response to
antiviral therapy has also been observed in HCV-infected
patients receiving DAAs in regimens without IFN. In particular,
in patients treated with sofosbuvir and RBV, IFN-k4-DG is
associated with slower early viral decay, owing to slower loss of
free virus and decreased drug efficacy, suggesting a functional
relevance of IFN-k4 in IFN-free DAA therapies [67].
Although the predictive power of this additional SNP was
rapidly confirmed by several studies [13,68], it is difficult to
explain conceptually why the production of this novel IFN-k
protein, which shows anti-HCV activity [64] and triggers an
antiviral response by inducing STAT1 and STAT2 phosphor-
ylation and upregulating the expression of ISGs [13,64], may
have a deleterious effect on antiviral treatment. In this regard,
new findings have been recently published that make more
evident the complexity of the phenomenon: (i) ss469415590
TT/DG polymorphisms promote the methylation of adjacent
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cytosine residues, as already suggested for IL-28B SNPs [44],
thereby influencing gene expression [68]; and (ii) ss469415590
genotypes seem to be not related to IFN-k2/3 or IFN-k1 gene
expression [69]. Further studies are needed to provide new
information so that we can start to understand the function of
this new IFN-k.
Closing Remarks
The recent identification of the genetic polymorphisms in the
IL-28B gene region (in both the IFN-k3 gene and the IFN-k4
gene) as predictors of CHC treatment outcome is certainly an
exciting finding. It provides new insights into virus–host
interaction, and appears to have immediate clinical utility,
not only as a diagnostic tool, but also as potential aid for both
patients and physicians in considering IFN-based therapy.
However, the treatment paradigm, especially in GT1 HCV
infection, is rapidly evolving, owing to the introduction of
DAAs in new highly active regimens. The impact of IFN-k3 and
IFN-k4 polymorphisms and their interplay in this setting appear
to be complex and need further investigation.
Nevertheless, it is evident that these findings could
represent an intriguing example of host genomic contribution
to disease progression and outcome, and provide the basis for
individualization of antiviral therapy.
Although, in the recent past, the assay for analysing the
so-called IL-28 polymorphism has been utilized and has
demonstrated clinical utility, many questions on the biological
processes and pathways involved remain open. Further
investigations on the following issues might help in clarifying
the importance of IFN-k3 and IFN-k4 variants in the patho-
genesis and management of patients suffering from pathologies
for which antiviral activity and IFN immune-modulatory activity
appear to be determinant:
 the role of the newly identified IFN-k4-TT/DG variants in the
context of new anti-HCV regimens and its relationship with
IL-28B polymorphisms;
 the impact of such variants in IFN-based therapy within the
context of other infections/pathologies (i.e. chronic hepati-
tis B and cancer).
 the relevance of IFN-k3 and IFN-k4 in the setting of
infections for which the immune-mediate response seems to
be relevant (i.e. viral acute infections).
Finally, it should be mentioned that, at present, most of the
suggestions that link specific SNPs with treatment response and
the outcome of infection have come from GWASs, which
constitute, basically, a gene-agnostic approach. SNPs reaching
the appropriate statistical threshold for a given phenotype can
appear anywhere in the genome, within, near or far away from
any coding sequence. Therefore we believe that the greatest
challenge lies in combining GWAS findings with additional
molecular data to functionally characterize the associations. The
advances in various -omics techniques have made possible to
investigate the effects of risk variants at intermediate molecular
levels, such as gene expression, methylation, protein abundance,
and metabolite levels. As disease pathogenesis involves a
complex interplay between host and virus (and this perfectly
applies to the issue described here, namely HCV infection), no
single molecular analysis is expected to fully unravel the disease
mechanism. Multiple molecular levels can interact and also show
plasticity in different physiological conditions and disease stages.
There is therefore a great need for new integrative approaches
that can combine data from different molecular levels and can
help to determine the causal path from genotype to phenotype.
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